Champions Oncology (CSBR)
Provides oncology research services, patient-derived models, testing platforms, and data offerings for biopharma.
$5.15
At close+0.15 (+3.00%)
In millions of USD, except per-share figures
| In millions | Q1 FY24Jul 2023 | Q2 FY24Oct 2023 | Q3 FY24Jan 2024 | Q4 FY24Apr 2024 | Q1 FY25Jul 2024 | Q2 FY25Oct 2024 | Q3 FY25Jan 2025 | Q4 FY25Apr 2025 | Q1 FY26Jul 2025 | Q2 FY26Oct 2025 | Q3 FY26Jan 2026 | Q4 FY26Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 12 | 12 | 14 | 14 | 13 | 17 | 12 | 14 | 15 | 17 | 14 |
| Cost of revenue | 8 | 7 | 8 | 7 | 7 | 7 | 7 | 7 | 8 | 7 | 9 | 7 |
| Gross profit | 5 | 5 | 4 | 7 | 7 | 6 | 10 | 5 | 6 | 8 | 8 | 7 |
| 7 | 7 | 7 | 7 | 6 | 5 | 6 | 7 | 7 | 8 | 8 | 8 | |
| Research & development | 3 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 |
| 5 | 4 | 5 | 5 | 4 | 4 | 4 | 5 | 4 | 5 | 6 | 5 | |
| Selling & marketing | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| General & administrative | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −3 | −2 | −3 | 0 | 1 | 1 | 4 | −2 | −1 | 0 | 0 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −2 | −3 | 0 | 1 | 1 | 5 | −2 | 0 | 0 | 0 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −3 | −2 | −3 | 0 | 1 | 1 | 4 | −2 | 0 | 0 | 0 | −1 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −3 | −2 | −3 | 0 | 1 | 1 | 4 | −2 | 0 | 0 | 0 | −1 |
| EPS, basic | −$0.19 | −$0.15 | −$0.19 | −$0.01 | $0.10 | $0.05 | $0.33 | −$0.13 | −$0.03 | $0.02 | −$0.02 | −$0.05 |
| EPS, diluted | −$0.19 | −$0.15 | −$0.19 | −$0.01 | $0.09 | $0.05 | $0.31 | −$0.13 | −$0.03 | $0.02 | −$0.02 | −$0.05 |
| Weighted average shares, basic | 14 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Weighted average shares, diluted | 14 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| EBITDA | −2 | −2 | −2 | 1 | 2 | 1 | 5 | −2 | 0 | 1 | 0 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −3 | −2 | −3 | 0 | 1 | 1 | 5 | −2 | 0 | 0 | 0 | 0 |